Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO)

Janice P. Dutcher, Peter H. Wiernik, Yelena Novik, Susan Garl, John Hughes, Joseph C. Arezzo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

MR, a 56 year old woman with a history of thrombocytopenia, was diagnosed with MDS. Bone marrow showed MDS, with dysplastic myeloid and erythoid lineages, decreased megakaryocytes and with 25% myeloblasts. Karyotype was 46XX. She was pancytopenic, requiring red cell and platelet transfusions and was given empiric antibiotics for neutropenic fever. ATO, 20 mg/day IV was given (32 doses) with a 3-day treatment break to allow diuresis. After 3 weeks of ATO, she was no longer neutropenic, nor did she require red cell or platelet transfusion. Her treatment was stopped due to development of clinically significant peripheral neuropathy. Serial Vibratron testing, used in this study to detect toxic distal axonopathy, demonstrated a doubling of vibratory sensation threshold during the 4 weeks of ATO treatment, from 3.7 vu at baseline to 8.8 vu at end of treatment. This correlated with the development in the last week fo treatment of clinical neuropathy in both upper and lower extremities. Now, 8 months later, with no further treatment, the neuropathy has improved considerably. She remains transfusion independent, with a normal white blood cell and granulocyte count, and normal hematocrit. Her platelet count is 7090,000/uL. Marrow biopsy at completion of ATO was hypercellular with improved maturation of myeloid and erythroid lines, and megakaryocytes. Her marrow was poorly aspirable throughout treatment and in vitro studies of marrow cultured with ATO could not be completed for technical reasons. This study is ongoing with accrual of patients with myeloid and lymphoid leukemias, MDS, lymphoma and myeloma.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART II
StatePublished - 2000
Externally publishedYes

Fingerprint

Platelets
Cells
Bone Marrow
Platelet Transfusion
Megakaryocytes
Therapeutics
Biopsy
Poisons
Lymphoid Leukemia
Granulocyte Precursor Cells
Myeloid Leukemia
Bone
Diuresis
Blood
Peripheral Nervous System Diseases
arsenic trioxide
Platelet Count
Karyotype
Leukocyte Count
Hematocrit

ASJC Scopus subject areas

  • Hematology

Cite this

Dutcher, J. P., Wiernik, P. H., Novik, Y., Garl, S., Hughes, J., & Arezzo, J. C. (2000). Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO). Blood, 96(11 PART II).

Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO). / Dutcher, Janice P.; Wiernik, Peter H.; Novik, Yelena; Garl, Susan; Hughes, John; Arezzo, Joseph C.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

Dutcher, JP, Wiernik, PH, Novik, Y, Garl, S, Hughes, J & Arezzo, JC 2000, 'Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO)', Blood, vol. 96, no. 11 PART II.
Dutcher JP, Wiernik PH, Novik Y, Garl S, Hughes J, Arezzo JC. Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO). Blood. 2000;96(11 PART II).
Dutcher, Janice P. ; Wiernik, Peter H. ; Novik, Yelena ; Garl, Susan ; Hughes, John ; Arezzo, Joseph C. / Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO). In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{ab0ee52f39444df4a49c8034121e9b69,
title = "Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO)",
abstract = "MR, a 56 year old woman with a history of thrombocytopenia, was diagnosed with MDS. Bone marrow showed MDS, with dysplastic myeloid and erythoid lineages, decreased megakaryocytes and with 25{\%} myeloblasts. Karyotype was 46XX. She was pancytopenic, requiring red cell and platelet transfusions and was given empiric antibiotics for neutropenic fever. ATO, 20 mg/day IV was given (32 doses) with a 3-day treatment break to allow diuresis. After 3 weeks of ATO, she was no longer neutropenic, nor did she require red cell or platelet transfusion. Her treatment was stopped due to development of clinically significant peripheral neuropathy. Serial Vibratron testing, used in this study to detect toxic distal axonopathy, demonstrated a doubling of vibratory sensation threshold during the 4 weeks of ATO treatment, from 3.7 vu at baseline to 8.8 vu at end of treatment. This correlated with the development in the last week fo treatment of clinical neuropathy in both upper and lower extremities. Now, 8 months later, with no further treatment, the neuropathy has improved considerably. She remains transfusion independent, with a normal white blood cell and granulocyte count, and normal hematocrit. Her platelet count is 7090,000/uL. Marrow biopsy at completion of ATO was hypercellular with improved maturation of myeloid and erythroid lines, and megakaryocytes. Her marrow was poorly aspirable throughout treatment and in vitro studies of marrow cultured with ATO could not be completed for technical reasons. This study is ongoing with accrual of patients with myeloid and lymphoid leukemias, MDS, lymphoma and myeloma.",
author = "Dutcher, {Janice P.} and Wiernik, {Peter H.} and Yelena Novik and Susan Garl and John Hughes and Arezzo, {Joseph C.}",
year = "2000",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO)

AU - Dutcher, Janice P.

AU - Wiernik, Peter H.

AU - Novik, Yelena

AU - Garl, Susan

AU - Hughes, John

AU - Arezzo, Joseph C.

PY - 2000

Y1 - 2000

N2 - MR, a 56 year old woman with a history of thrombocytopenia, was diagnosed with MDS. Bone marrow showed MDS, with dysplastic myeloid and erythoid lineages, decreased megakaryocytes and with 25% myeloblasts. Karyotype was 46XX. She was pancytopenic, requiring red cell and platelet transfusions and was given empiric antibiotics for neutropenic fever. ATO, 20 mg/day IV was given (32 doses) with a 3-day treatment break to allow diuresis. After 3 weeks of ATO, she was no longer neutropenic, nor did she require red cell or platelet transfusion. Her treatment was stopped due to development of clinically significant peripheral neuropathy. Serial Vibratron testing, used in this study to detect toxic distal axonopathy, demonstrated a doubling of vibratory sensation threshold during the 4 weeks of ATO treatment, from 3.7 vu at baseline to 8.8 vu at end of treatment. This correlated with the development in the last week fo treatment of clinical neuropathy in both upper and lower extremities. Now, 8 months later, with no further treatment, the neuropathy has improved considerably. She remains transfusion independent, with a normal white blood cell and granulocyte count, and normal hematocrit. Her platelet count is 7090,000/uL. Marrow biopsy at completion of ATO was hypercellular with improved maturation of myeloid and erythroid lines, and megakaryocytes. Her marrow was poorly aspirable throughout treatment and in vitro studies of marrow cultured with ATO could not be completed for technical reasons. This study is ongoing with accrual of patients with myeloid and lymphoid leukemias, MDS, lymphoma and myeloma.

AB - MR, a 56 year old woman with a history of thrombocytopenia, was diagnosed with MDS. Bone marrow showed MDS, with dysplastic myeloid and erythoid lineages, decreased megakaryocytes and with 25% myeloblasts. Karyotype was 46XX. She was pancytopenic, requiring red cell and platelet transfusions and was given empiric antibiotics for neutropenic fever. ATO, 20 mg/day IV was given (32 doses) with a 3-day treatment break to allow diuresis. After 3 weeks of ATO, she was no longer neutropenic, nor did she require red cell or platelet transfusion. Her treatment was stopped due to development of clinically significant peripheral neuropathy. Serial Vibratron testing, used in this study to detect toxic distal axonopathy, demonstrated a doubling of vibratory sensation threshold during the 4 weeks of ATO treatment, from 3.7 vu at baseline to 8.8 vu at end of treatment. This correlated with the development in the last week fo treatment of clinical neuropathy in both upper and lower extremities. Now, 8 months later, with no further treatment, the neuropathy has improved considerably. She remains transfusion independent, with a normal white blood cell and granulocyte count, and normal hematocrit. Her platelet count is 7090,000/uL. Marrow biopsy at completion of ATO was hypercellular with improved maturation of myeloid and erythroid lines, and megakaryocytes. Her marrow was poorly aspirable throughout treatment and in vitro studies of marrow cultured with ATO could not be completed for technical reasons. This study is ongoing with accrual of patients with myeloid and lymphoid leukemias, MDS, lymphoma and myeloma.

UR - http://www.scopus.com/inward/record.url?scp=33748578307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748578307&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748578307

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -